Funding for this research was provided by:
Medical Research Council (171339, 171339 and 171339)
Efficacy and Mechanism Evaluation Programme (11/100/50)
Cancer Research UK (A13363 and 162082)
Novartis Pharmaceuticals UK Limited (158519)
Janssen Pharmaceuticals (163301)
Astellas Pharma US (163026)
Received: 10 August 2018
Accepted: 19 January 2019
First Online: 29 May 2019
Ethics approval and consent to participate
: The FOCUS4 and STAMPEDE trials have received favourable opinion by the relevant Research Ethics Committee (13/SC/0111 and 04/MRE07/35).
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.